Skip to main content

Table 3 Summary of the cited meta-analyses and this study

From: The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis

Survival outcomesaTotal PatientsOSFFSDMFSLRFS
Chen 2015 [17]206HR 0.70,
95% CI 0.39–1.26
FERR 0.51,
95% CI 0.28–0.95
RR 1.65,
95% CI 0.95–2.86
Song 2015 [18]798HR 0.52,
95% CI 0.21–1.29
HR 0.66,
95% CI 0.49–0.90
HR 0.60,
95% CI 0.39–0.98
HR 0.66,
95% CI 0.16–2.65
Ouyang 2019 [19]1418FEFEFEFE
Chen 2018 [20]1193HR 0.75,
95% CI 0.57–0.99
HR 0.70,
95% CI 0.56–0.86
HR 0.68,
95% CI 0.51–0.90
HR 0.70,
95% CI 0.48–1.01
Tan 2018 [21]2802HR 0.77,
95% CI 0.60–0.98
HR 0.69,
95% CI 0.57–0.84
HR 0.63,
95% CI 0.47–0.83
HR 0.66,
95% CI 0.45–0.96
Wang23113-year: HR 0.70,
95% CI 0.55–0.89;
5-year: HR 0.77,
95% CI 0.62–0.94
3-year: HR 0.67,
95% CI 0.55–0.80;
5-year: HR 0.70,
95% CI 0.58–0.83
3-year: HR 0.58,
95% CI 0.45–0.74;
5-year: HR 0.69,
95% CI 0.55–0.87
3-year: HR 0.69,
95% CI 0.50–0.95;
5-year: HR 0.66,
95% CI 0.51–0.86
  1. OS overall survival; FFS failure-free survival; DMFS distant metastasis-free survival; LRFS locoregional relapse-free survival; HR hazard ratio; 95% CI 95% confidence interval; FE fail to extract
  2. a data of randomized clinical trials